Contract research firm Parexel is said to garner takeover interest from Private equity giant EQT and a consortium of three other buyout majors.
A consortium of Cinven, Centerbridge and GTCR is working on a bid for the contract research organization, according to traders, who cited a Bloomberg report.
Parexel is said to have received interest from about 10 parties.
Bloomberg reported in April Parexel’s PE owner Pamplona Capital Management was exploring a sale of the company in a deal that could value Parexel at about $9B including debt.
The potential sale comes after some other big deals for CROs earlier this year including Thermo Fisher’s (NYSE:TMO) planned $17B deal for PPD (NASDAQ:PPD) and Icon PLC’s agreement to purchase PRA Health (NASDAQ:PRAH) for about $12B.
Source: Seeking Alpha
Can’t stop reading? Read more
Luckin investor Centurium in talks over £1bn Costa Coffee takeover
Luckin investor Centurium in talks over £1bn Costa Coffee takeover Centurium Capital, the Chinese...
“Cash is king, and anything else is an opinion”: private equity’s return to fundamentals
“Cash is king, and anything else is an opinion”: private equity’s return to fundamentals After a...
Neuberger Berman closes $7.3bn private debt fund, surpassing target
Neuberger Berman closes $7.3bn private debt fund, surpassing target Neuberger Berman has announced...